Lawrence N. Kwong

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma

  Nature Communications · 2026-06-26

• Supplementary Table S2 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy

  2026-06-17

• Supplementary Table S3 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy

  2026-06-17

• Supplementary Figure S3 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy

  2026-06-17

• Supplementary Table S1 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy

  2026-06-17

• Data from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy

  2026-06-17

• Supplementary Figure S2 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy

  2026-06-17

• Supplementary Table S4 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy

  2026-06-17

• Supplementary Figure S1 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy

  2026-06-17

• Supplementary Table S6 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy

  2026-06-17

• Supplementary Table S5 from Clinicogenomic and Histopathologic Analyses of Supermassive Intrahepatic Cholangiocarcinoma and the Role of Ablative Radiotherapy

  2026-06-17

• FGFR1 but not S6K1/2 drives intrinsic BRAF inhibitor resistance in melanoma

  Cell Death Discovery · 2026-05-19

• A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture

  Cancer Discovery · 2026-05-13

• Abstract 3075: FGFR2b is a highly prevalent and actionable cell surface target in intrahepatic cholangiocarcinoma

  Cancer Research · 2026-04-03

• Global patterns of mutational profiles in biliary tract cancer

  Journal of Hepatology · 2026-03-01 · 1 citations

• Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer

  Cell Reports Medicine · 2026-02-01

• Editor’s Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

  Cancer Discovery · 2025-12-02

• Supplementary Figures S6-S10 from Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma

  2025-11-26

• Supplementary Tables from Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma

  2025-11-26

• Supplementary Figures S1-S5 from Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma

  2025-11-26